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SULFONYLUREA DRUGS TO HUMAN SERUM ALBUMIN DUE TO
GLYCATION AND FATTY ACIDS
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Abstract
This report examines the use of high-performance affinity chromatography as a screening tool for
studying the change in binding by sulfonylurea drugs to the protein human serum albumin (HSA)
during diabetes. The effects of both the non-enzymatic glycation of HSA and the presence of fatty
acids on these interactions were considered using a zonal elution format. It was found that there
was significant increase (i.e., 2.7 to 3.6-fold) in the relative retention of several sulfonylurea drugs
(i.e., acetohexamide, tolbutamide, glybenclamide and gliclazide) on columns containing normal
versus glycated HSA. The addition of various long chain fatty acids to the mobile phase gave the
same trend in retention for the tested drugs on both the HSA and glycated HSA columns, generally
leading to lower binding. Most of the fatty acids examined produced similar or moderately
different relative shifts in retention; however, palmitic acid was found to produce a much larger
change in retention on columns containing glycated HSA versus normal HSA under the conditions
used in this study.
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1. Introduction
Human serum albumin (HSA) is an important carrier protein in serum for many drugs, small
hormones and fatty acids [1,2]. In the presence of glucose, HSA can undergo the non-
enzymatic addition of this sugar to lysine residues or the N-terminus in a process known as
glycation. This process initially forms a reversible Schiff base that can later rearrange to
form a stable ketoamine, or Amadori product [3-5]. Healthy individuals have between
6-15% of HSA present as glycated HSA (G-HSA) in serum, while persons with type II
diabetes (i.e., a condition in which there is an elevated level of glucose in blood) often have
15-30% glycated HSA in serum [5,6]. Previous studies have indicated that glycation-related
modifications can occur near the two main drug binding sites on HSA [3,4,7-9]. It has been
proposed that presence of such modifications can influence the binding of drugs and other
substances to this protein [7-9].
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Sulfonylureas are drugs commonly used to treat type II diabetes and include acetohexamide,
tolbutamide, glybenclamide (i.e., glyburide) and gliclazide [10-12]. These drugs are highly
bound to serum proteins, and in particular to HSA [13,14]. It has been shown for some
sulfonylureas (e.g., acetohexamide and tolbutamide) that these interactions occur at both of
the major binding sites of HSA (i.e., Sudlow sites I and II) [15-17]. High-performance
affinity chromatography (HPAC) is a tool that has recently been used in detailed studies to
characterize the binding of acetohexamide and tolbutamide with HSA to examine the effects
of glycation on the site-specific interactions of these drugs and other agents at Sudlow sites I
and II [15-18]. Along with glycation, the effect on these interactions due to the binding of
HSA to fatty acids (which may also be elevated during diabetes) is also of interest because
of the possible combined effect these factors can have on drug-protein interactions during
diabetes [6]. This work will explore the use of HPAC columns containing HSA or G-HSA in
a screening assay to compare of the effects of glycation and the presence of various fatty
acids found in serum on the binding of common sulfonylurea drugs to HSA. This work
should provide some initial clues as to the relative effects of glycation and binding by fatty
acids on these interactions.
2. Experimental
2.1. Reagents
The HSA (essentially fatty-acid free, lot no. 104K7636), G-HSA (essentially fatty-acid free,
lot 115K6108), lauric acid, linoleic acid, myristic acid, oleic acid, palmitic acid, stearic acid,
acetohexamide, gliclazide, glybenclamide and tolbutamide were obtained from Sigma-
Aldrich (St. Louis, MO, USA). The G-HSA was prepared commercially using in vitro
methods under proprietary conditions by incubating a fixed concentration of D-glucose with
HSA at 37 °C for periods of time that were no longer than a week. The preparation of G-
HSA that was used in this study contained the equivalent of 3.6 mol hexose/mol HSA, as
reported by the manufacturer. Mass spectrometric studies on the location and types of
modifications that occur in this type of preparation have been reported in Refs. [7,8],
including information on modifications that have been noted at or near Sudlow sites I and II
of glycated HSA. The Nucleosil 300-7 silica (7 μm particle diameter, 300 Å pore size) was
from Macherey Nagel (Düren, Germany). Reagents for the bicinchoninic acid (BCA) protein
assay were from Pierce (Rockford, IL, USA). All solutions were prepared using water from
a Barnstead Nanopure water system (Dubuque, IA, USA).
2.2. Apparatus
The chromatographic system consisted of a Hitachi L-6000 pump (Pleasanton, CA, USA), a
ThermoSeparations SpectraSystem AS3000 autosampler (Waltham, MA, USA) equipped
with a 10 μL sample loop, and a Waters 481 UV detector (Milford, MA, USA). The
detection wavelengths were as follows: 248 nm, acetohexamide; 226 nm, gliclazide and
tolbutamide; and 228 nm, glybenclamide. The columns were held at 37 (± 0.1)°C by using a
water jacket (Fisher Scientific, Pittsburgh, PA, USA) and recirculating water bath (CH/P
Bath and Circulator Model 2067, Forma Scientific Inc., Marietta, OH, USA). Data were
acquired using in-house programs written in LabView 8.0 (National Instruments, Austin,
TX, USA) and processed using PeakFit 4.12 (SeaSolve Software, San Jose, CA, USA).
2.3. Methods
Nucleosil 300-7 silica was converted into diol silica [19] and portions of this diol silica were
used to immobilize HSA or G-HSA by the Schiff base method [20]. The immobilization of
HSA by this Schiff base method has been shown to mainly occur at the N-terminus or at a
few lysines that are not located at Sudlow sites I or II and that tend to be different from the
residues that are involved in glycation [7,8,21]. The Schiff base method is a relatively
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simple immobilization technique that has already been demonstrated to give binding data for
sulfonylurea drugs that are in good agreement with solution phase results for both glycated
HSA and normal HSA [13,15-17]; however, other immobilization methods based on the
coupling of HSA through its free cysteine [22] or through entrapment [23] could also be
utilized for such work. Part of the diol silica was taken through the Schiff base method with
no protein being added to create a control support. All of the final supports were stored in
pH 7.4, 67 mM potassium phosphate buffer at 4°C until use. The protein content of the HSA
and G-HSA supports was determined in triplicate by using a BCA assay, with soluble HSA
or G-HSA being used as the standard and the control support being used as the blank. The
HSA support was found to contain 25 (± 2.5) mg HSA per g silica, and the G-HSA support
contained 15.4 (± 0.7) mg G-HSA per g silica.
Each column used in this study was 2.0 cm × 2.1 mm I.D. and was downward slurry packed
with the desired support at 3500 psi (24.1 MPa) for 2 h with pH 7.4, 67 mM potassium
phosphate buffer being utilized as the packing solution. These columns were stored at 4°C in
pH 7.4, 67 mM phosphate buffer and were used over the period a few months (approximate
total run time, 100 h at 1 ml/min). It has been found in related studies that such columns are
stable for at least six months under these operating conditions [20].
Stock sample solutions were prepared by dissolving 100 μM acetohexamide, gliclazide,
glybenclamide or tolbutamide in pH 7.4, 67 mM potassium phosphate buffer. In the case of
glybenclamide, 850 μM β-cyclodextrin was also added to the solution to act as a solubilizing
agent, as has been used in previous work with other low solubility drugs on HSA columns
[24]. The stock solutions were diluted using pH 7.4, 67 mM potassium phosphate buffer to
give 5 μM working samples of acetohexamide, gliclazide or tolbutamide and a 25 μM
working solution of glybenclamide (note: a higher concentration of glybenclamide was
required because of its high retention and broad peaks on the HSA and G-HSA columns,
which made it difficult to detect lower concentration samples). Although these sample
concentrations were higher than the typical levels of these drugs in serum at therapeutic
doses [25], it is important to note in this work that only a small pulse of each drug was
injected to probe the overall binding of the drug with normal HSA or glycated HSA. It was
also found that no significant changes in retention occurred when using slightly higher
sample concentrations of these drugs, indicating that linear elution conditions were present
under the conditions used in this study (i.e., conditions in which the results would reflect
those that would be obtained in solution at low concentrations of each drug versus HSA)
[26]. It was determined in control experiments that the presence of β-cyclodextrin in the
glybenclamide samples did not have any significant effect on the interactions between HSA
and this drug, as has been noted with other solutes [24].
All samples were injected in triplicate at 37°C and at 0.5 mL/min in the presence of pH 7.4,
67 mM potassium phosphate buffer or the same buffer containing a known concentration of
a fatty acid (see Table 2 for a list of the fatty acids and concentrations used in this study).
Similar injections of a 5 μM solution of sodium nitrate (i.e., a non-retained solute) in pH 7.4,
67 mM phosphate buffer were made to measure the void time of each column. No
significant changes in retention were noted when using slower flow rates for injection, as
has been noted in similar work with other drugs on HSA columns [26]. Injections on the
control column indicated that all of the tested drugs had no significant non-specific retention
on this support (i.e., binding that made up less than 3% of the total retention on the HSA or
G-HSA columns).
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3. Results and Discussion
Affinity chromatography has been shown in the past to be a useful tool in characterizing and
screening the overall affinity of various drugs with normal HSA. For instance, the retention
factor (k) measured for an injected drug on an affinity column can be directly related to the
global affinity of the drug for an immobilized protein such as HSA [26], as shown in Eqn.
(1).
(1)
In this equation, KA1 through KAn are the association equilibrium constants for binding sites
1 through n, n1 through nn represent the number of each type of site in the column, mL is the
moles of binding sites in the column, and VM is the column void volume. In this case, the
global association equilibrium constant is the summation of the KA n terms, as could be used
to examine a drug with multiple sites of interaction with HSA (e.g., Sudlow sites I and II).
Figure 2 shows some typical chromatograms obtained when a small amount of a
sulfonylurea drug was injected onto affinity columns containing normal or glycated HSA.
Table 1 summarizes the retention factors measured for each of the tested drugs. It was found
that glycated HSA consistently gave higher retention, and thus stronger binding, than normal
HSA. After these results were normalized for the different protein contents of the columns,
the glycated HSA column gave a 2.7 to 3.6-fold higher retention than normal HSA for the
injected drugs. The relative change in retention was approximately the same for all of the
tested sulfonylureas regardless of the different structures of their side chains. These results
agreed with control experiments based on ultrafiltration using similar preparations of normal
HSA and glycated HSA plus low-to-therapeutic levels of the drugs and physiological
concentrations of each protein [13]. According to Eqn. (1), this result would correspond to a
proportional difference in the global affinities of these two protein preparations for the
drugs.
The trends noted in Table 1 agree with recent observations that have been made in detailed
frontal analysis studies and competition studies examining the interactions of acetohexamide
and tolbutamide with normal HSA versus glycated HSA [16,17]. In a separate study, no
statistically significant change in the overall percent binding of glybenclamide was seen in
going from normal HSA to glycated HSA [27]. The different conclusions reached in this
current study and in Ref. [27] may reflect changes in binding affinity with the level of
glycation of HSA [16,17]. However, Ref. [27] also involved the measurement of percent
binding and attempted to compare changes in this value for drug samples with 98% or
greater binding to HSA; under these conditions, an increase in binding affinity with
glycation would have been difficult to observe with the experimental method that was
employed. This was not an issue with the HPAC method used in this current report because
an increase in affinity would lead to a proportional increase in retention for even a drug with
a high affinity for a protein.
Another way in which zonal elution can be employed is to study the effect of one solute on
the binding of another to HSA [26]. This report compared the effect of several long chain
fatty acids on the overall binding of sulfonylurea drugs to normal HSA versus glycated
HSA. Table 2 lists the fatty acids and concentrations that were examined (note:
concentrations up to 100-fold below normal serum concentrations were selected in this case
to simplify the analysis and emphasize the higher affinity interactions that might occur
between these additives and injected drugs). Typical chromatograms that were obtained in
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the absence and presence of these fatty acids are shown in Figure 2. The addition of most of
the fatty acids produced a decrease in the observed retention for the sulfonylurea drugs on
either normal HSA or glycated HSA. It is known that fatty acids can lead to a variety of
effects in the binding of drugs to normal HSA, including direct competition and multisite
interactions that can include allosteric effects [28].
It was found under these conditions for most of the tested drugs that there was a gradual
change in the observed retention as the fatty acid concentration was increased (see example
in Figure 3). Table 2 summarizes the overall change in retention that was noted on both the
normal HSA and glycated HSA columns for each of the tested drugs. Similar trends were
noted in control experiments using ultrafiltration and the same drugs and fatty acids [13]. In
all cases except one, a decrease in retention for the sulfonylurea drugs was seen as the
concentration of fatty acids in the mobile phase was increased (note: the single exception
was for glybenclamide in the presence of myristic acid, and even in this case there was only
a slight increase in retention). Acetohexamide, gliclazide and tolbutamide gave overall
changes in retention that were similar between the normal and glycated HSA columns.
When compared to these other drugs, glybenclamide gave similar or lower changes in
retention except for a small increase seen in the presence of linoleic acid and normal HSA;
this latter difference may have been due to the larger structure and lower solubility of
glybenclamide or secondary effects due to the use of a small amount of β-cyclodextrin in the
glybenclamide samples as a solubilizing agent.
Fatty acids which lead to only relatively small changes in the retention for sulfonylurea
drugs on the normal and glycated HSA columns (i.e., values in Table 2 that varied by less
than 10%) included myristic acid and oleic acid in work with acetohexamide, glyclazide and
tolbutamide; and lauric acid, linoleic acid, and oleic acid with glybenclamide. Fatty acids
which created moderate differences in retention shifts on the two types of HSA columns
(i.e., values in Table 2 that differed by 11-25%) included lauric acid, linoleic acid and stearic
acid in experiments conducted with acetohexamide; lauric acid, linoleic acid, and stearic
acid in work with gliclazide; lauric acid, linoleic acid, and stearic acid for tolbutamide; and
myristic acid and stearic acid for glybenclamide. Palmitic acid demonstrated a much larger
variation in retention shifts that was seen for any of the other tested fatty acids. In this latter
case, the values in Table 2 for the normal HSA and glycated HSA columns differed by
41-73% for all of the tested drugs under the conditions used in this study.
4. Conclusions
This report used high-performance affinity columns containing normal HSA or glycated
HSA to examine the changes in overall affinity and binding that occur for various
sulfonylurea drugs with such proteins. It was found for all of the tested drugs that the
glycated HSA had higher overall binding under linear elution conditions for the protein
preparations that were used in this study. This binding also tended to decrease in the
presence of several common fatty acids that are found in serum. In many cases the effects of
these fatty acids on the binding of sulfonylurea drugs were similar or only moderately
different for normal HSA versus glycated HSA. However, for palmitic acid there was a
much larger change in this binding to glycated HSA compared to normal HSA.
This work demonstrates how HPAC columns can be used as screening tools to examine and
compare multiple effects on the binding of drugs to proteins such as HSA. The trends
observed in this study indicate that both protein glycation and the presence of fatty acids in
serum, as occurs during diabetes, can alter the overall binding of sulfonylurea drugs to HSA.
More detailed studies are now in progress to examine these effects over a broader range of
conditions and levels of protein glycation, as well as to determine the mechanisms by which
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fatty acids may affect the interactions of sulfonlyurea drugs with normal HSA or glycated
HSA. The expected result of this work is a better description of how the serum protein
interactions of sulfonylurea drugs may be altered during diabetes, which should allow for a
more effective use of such agents in treating this disease.
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Figure 1.
Structures of sulfonylurea drugs examined in this study.
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Figure 2.
Chromatograms for acetohexamide on columns containing normal HSA or glycated HSA in
presence of only pH 7.4, 67 mM potassium phosphate buffer or normal HSA in the presence
of the same buffer containing 70 nM linoleic acid.
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Figure 3.
Change in retention factor for glyblenclamide on columns containing (a) normal HSA or (b)
glycated HSA in the presence of increasing concentrations of linoleic acid. The errors bars,
which are similar in size to the data markers in most cases, represent a range of ± 1 S.D.
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Table 1
Retention of various sulfonylurea drugs on columns containing normal or glycated HSA
Drug/protein Retention factor, k
Normalized retention factor,
k/(protein content)
Normal HSA
Acetohexamide 4.7 (± 0.4) 0.19 (± 0.02)
Glybenclamide 1.05 (± 0.07) 0.042 (± 0.005)
Gliclazide 2.5 (± 0.1) 0.099 (± 0.011)
Tolbutamide 37 (± 2) 1.49 (± 0.15)
Glycated HSA
Acetohexamide 8.6 (± 0.2) 0.56 (± 0.03)
Glybenclamide 2.3 (± 0.1) 0.15 (± 0.01)
Gliclazide 4.4 (± 0.1) 0.28 (± 0.02)
Tolbutamide 61 (± 4) 4.0 (± 0.3)
a
All of these studies were conducted at 37°C in the presence of pH 7.4, 67 mM potassium phosphate buffer. The values in parentheses represent a
range of ± 1 S.D.
b
These normalized retention factors were calculated by dividing the listed retention factors by a measured protein content for the given supports of
25 (± 2.5) mg HSA per g silica or 15.4 (± 0.7) mg G-HSA per g silica.
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Table 2
Relative change in retention factor for sulfonylurea drugs on a normal and glycated HSA columns in the
presence of various fatty acids
Fatty acid
(Concentration range)
Drug and relative change in retention
Acetohexamide Gliclazide Tolbutamide Glybenclamideb
Normal HSA
Lauric acid (0-60 nM) 27% 41% 26% 8%
Linoleic acid (0-250 nM) 3% 4% 4% 15%
Myristic acid (0-30 nM) 27% 33% 22% (7%)b
Oleic acid (0-546 nM) 15% 8% 16% 11%
Palmitic acid (0-400 nM) 10% 15% 11% 11%
Stearic acid (0-80 nM) 5% 4% 4% 2%
Glycated HSA
Lauric acid (0-6 nM) 14% 18% 13% 15%
Linoleic acid (0-250 nM) 18% 22% 18% 17%
Myristic acid (0-30 nM) 25% 31% 23% 15%
Oleic acid (0-546 nM) 9% 15% 11% 12%
Palmitic acid (0-400 nM) 81% 79% 84% 52%
Stearic acid (0-80 nM) 20% 26% 20% 18%
a
All of these studies were conducted at 37°C in the presence of pH 7.4, 67 mM potassium phosphate buffer.
b
All of the above relative changes represent a decrease in retention except for glybenclamide in the presence of myristic acid, which gave a slight
increase in retention at the highest tested concentration of this fatty acid.
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